Were Jeff E. Knight’s CRNX share sales made under a Rule 10b5-1 plan?

Yes. The sale was executed automatically under a Rule 10b5-1 trading plan. The plan was adopted by Jeff E. Knight on December 12, 2025, indicating the sale timing was pre-arranged rather than decided on the transaction date.

Crinetics officer exercises options, sells 85K shares

Crinetics Pharmaceuticals Chief Dev. & Operating Officer Jeff E. Knight reported an exercise-and-sale transaction in company stock.

Filing Impact

(Very High)

Filing Sentiment

(Very Negative)

Form Type

Rhea-AI Filing Summary

Crinetics Pharmaceuticals Chief Dev. & Operating Officer Jeff E. Knight reported an exercise-and-sale transaction in company stock. On April 8, 2026, he exercised stock options to acquire a total of 78,434 shares of Common Stock at exercise prices of $23.98, $20.02, and $19.64 per share.

On the same date, Knight sold 85,163 shares of Common Stock in open market transactions at a volume weighted average price of $40.10 per share, with individual sale prices ranging from $40.00 to $40.34. The sale was executed automatically under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly holds 105,289 shares of Crinetics common stock.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 7 txns

Insider Knight Jeff E.

Role Chief Dev. & Operating Officer

Sold 85,163 shs ($3.42M)

Approx. gross sale proceeds $3.42M

Approx. exercise cost $1.76M

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	49,474	$0.00	$0.00
Exercise	Stock Option (Right to Buy)	9,624	$0.00	$0.00
Exercise	Stock Option (Right to Buy)	19,336	$0.00	$0.00
Exercise	Common Stock	49,474	$23.98	$1.19M
Exercise	Common Stock	9,624	$20.02	$193K
Exercise	Common Stock	19,336	$19.64	$380K
Sale	Common Stock	85,163	$40.10	$3.42M

Holdings After Transaction: Stock Option (Right to Buy) — 139,593 contracts (Direct); Common Stock — 105,289 shares (Direct)

Footnotes (5)

F1. The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.
F2. The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sale price of $40.10 per share. The range of sale prices on the transaction date was $40.00 to $40.34. Detailed information on the exact number of shares can be obtained from the Issuer upon request.
F3. 25% of the shares subject to the option vested on August 30, 2022, and the remaining number of shares subject to the option vested monthly thereafter in thirty-six equal installments.
F4. 1/48th of the shares subject to the option vested monthly measured from the vesting commencement date of February 28, 2022.
F5. The option is exercisable as follows: 1/48th of the shares subject to the option vest monthly measured from the vesting commencement date of March 1, 2023, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

Key Figures

Options exercised: 78,434 shares Exercise price 1: $23.98 per share Exercise price 2: $20.02 per share +5 more

8 metrics

Options exercised 78,434 shares Total underlying Common Stock acquired via option exercises on April 8, 2026

Exercise price 1 $23.98 per share Stock Option (Right to Buy) conversion or exercise price

Exercise price 2 $20.02 per share Stock Option (Right to Buy) conversion or exercise price

Exercise price 3 $19.64 per share Stock Option (Right to Buy) conversion or exercise price

Shares sold 85,163 shares Common Stock sold in open market transactions on April 8, 2026

VWAP sale price $40.10 per share Volume weighted average sale price for Common Stock sales

Sale price range $40.00–$40.34 per share Range of sale prices for the reported Common Stock transactions

Post-transaction holdings 105,289 shares Common Stock held directly by Knight after the transactions

Key Terms

Rule 10b5-1 trading plan, volume weighted average sale price, Stock Option (Right to Buy), open market transactions, +1 more

5 terms

Rule 10b5-1 trading plan financial

"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

volume weighted average sale price financial

"with a volume weighted average sale price of $40.10 per share"

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

open market transactions financial

"The common stock was sold by the Reporting Person in open market transactions on the transaction date"

Open market transactions are the buying and selling of a company’s shares or other securities conducted on public exchanges or through the wider market rather than through private deals or negotiated placements. They matter to investors because these trades change supply and demand in real time—like shoppers affecting a store’s inventory—and so can move prices, signal management or investor sentiment, affect liquidity, and alter ownership stakes that influence future returns and risk.

Exercise or conversion of derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CRNX executive Jeff E. Knight report in this Form 4?

Jeff E. Knight reported exercising stock options and selling shares of Crinetics Pharmaceuticals (CRNX). He exercised options for 78,434 shares and sold 85,163 shares in open market trades, while continuing to hold 105,289 CRNX shares directly.

How many Crinetics (CRNX) shares did Jeff E. Knight sell and at what price?

Knight sold 85,163 shares of Crinetics common stock in open market transactions. The volume weighted average sale price was $40.10 per share, with individual sale prices ranging from $40.00 to $40.34 on the transaction date.

How many CRNX shares does Jeff E. Knight hold after these transactions?

After the reported transactions, Knight directly holds 105,289 shares of Crinetics common stock. This figure reflects his position following the option exercises and the open market sale disclosed in the Form 4 filing.

What stock options did Jeff E. Knight exercise for Crinetics (CRNX)?

Knight exercised three stock option grants covering a total of 78,434 shares of CRNX common stock. The underlying options had exercise prices of $23.98, $20.02, and $19.64 per share, with original expirations in 2031, 2032, and 2033.

What is meant by volume weighted average sale price in this CRNX Form 4?

The volume weighted average sale price of $40.10 reflects the average price across all reported CRNX share sales. Individual trades occurred between $40.00 and $40.34 per share, and the weighted average incorporates each trade’s share volume and price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 04/10/2026 - 04:33 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Knight Jeff E.

(Last)

(First)

(Middle)

C/O CRINETICS PHARMACEUTICALS, INC.

6055 LUSK BOULEVARD

(Street)

SAN DIEGO

CALIFORNIA

92121

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Crinetics Pharmaceuticals, Inc. [ CRNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Dev. & Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/08/2026		M		49,474	A	$23.98	161,492	D
Common Stock	04/08/2026		M		9,624	A	$20.02	171,116	D
Common Stock	04/08/2026		M		19,336	A	$19.64	190,452	D
Common Stock	04/08/2026		S⁽¹⁾		85,163	D	$40.1⁽²⁾	105,289	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$23.98	04/08/2026		M			49,474	⁽³⁾	09/01/2031	Common Stock	49,474	$0	63,027	D
Stock Option (Right to Buy)	$20.02	04/08/2026		M			9,624	⁽⁴⁾	02/29/2032	Common Stock	9,624	$0	10,589	D
Stock Option (Right to Buy)	$19.64	04/08/2026		M			19,336	⁽⁵⁾	03/01/2033	Common Stock	19,336	$0	65,977	D

Explanation of Responses:

1. The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.

2. The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sale price of $40.10 per share. The range of sale prices on the transaction date was $40.00 to $40.34. Detailed information on the exact number of shares can be obtained from the Issuer upon request.

3. 25% of the shares subject to the option vested on August 30, 2022, and the remaining number of shares subject to the option vested monthly thereafter in thirty-six equal installments.

4. 1/48th of the shares subject to the option vested monthly measured from the vesting commencement date of February 28, 2022.

5. The option is exercisable as follows: 1/48th of the shares subject to the option vest monthly measured from the vesting commencement date of March 1, 2023, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

Remarks:

	/s/ Tobin Schilke, as attorney-in-fact	04/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

Crinetics officer exercises options, sells 85K shares

Rhea-AI Filing Summary

Positive

Negative